Health Condition 1: H903- Sensorineural hearing loss, bilateral
Conditions
Interventions
Intervention1: NIL: NIL
Intervention2: MedTech Cochlear Implant System: Unilateral cochlear implantation of HCL Cochlear
Implant System in patients with severe to profound bilateral hearing loss in ad
Sponsors
HCL TECHNOLOGIES LIMITED
Eligibility
Inclusion criteria
Inclusion criteria: 1.18 years of age or older 2.Severe-to-profound, sensorineural hearing loss ( >70 dB), determined by pure tune at 500Hz, 1000Hz and 2000Hz 3.bilateral or Postlingual onset of severe or profound hearing loss 4.Limited benefit from appropriate binaural hearing aids (verified by standard clinical practice), as defined by aided test scores of 50% correct or less in the ear to be implanted (60% or less in the best-aided listening condition) on tests of open set sentence recognition. I. Consistent with the Minimum Speech Test Battery (2011), it is required that all subjects be evaluated 5.Moderate to profound hearing loss in the low frequencies and profound (= 90 dB HL) hearing loss in the mid to high speech frequencies 6.eBERA – Electrical brainstem evoked response audiometry to ensure benefit from the Implant. eBERA can be performed during surgery itself.
Exclusion criteria
Exclusion criteria: 1.Sensorineural severe-to-profound hearing loss greater than 20 years at = 2 kHz and above 2.Simultaneous bilateral cochlear implantation or prior cochlear implantation in the ear to be implanted 3.Medical or psychological conditions that contraindicate undergoing general anaesthesia or surgery 4.Ossification, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, as confirmed by medical examination 5.Hearing impairment due to lesion or neuropathy of the acoustic nerve, VIII nerve or central auditory pathway (audio Neuropathy Spectrum disorder). 6.Active middle-ear infection 7.Tympanic membrane perforation 8.Unwillingness or inability of the candidate to comply with all investigational requirements as determined by the Investigator 9.Patients with existing CSF shunts or drains, existing perilymph fistula, skull fracture or CSF leak 10.Patients with recurrent episodes of bacterial meningitis 11.Any other Cochlear Implant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Performance – To evaluate preoperative to 3 month’s post-activation performance outcomes in the best unilateral listening condition Safety – Report of medical/surgical and device related adverse events with regard to type, frequency and seriousness at 3 months post activation Timepoint: Preoperative to 3 month’s post-activation | — |
Secondary
| Measure | Time frame |
|---|---|
| NATimepoint: NA | — |
Countries
India
Contacts
Public ContactDr Sreedhar Bunga
HCL TECHNOLOGIES LIMITED
Outcome results
None listed